Scott Lindhorst, MD
Medical Oncology · Charleston, SCNPI 1851503551
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,175 of the $6,918 with a category attached, or 74.8%. BTG International Inc. accounts for 86.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $5,991 and has fallen 99.5% since, to $27 in 2022.
Across 7 payments — averaging $988.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BTG International Inc.$6K
- Bayer$900
- Novocure Inc.$27
Across 25 payments — averaging $4321.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$65K
- Novocure GmbH$33K
- Servier Bioinnovation$7K
- Novocure Inc.$3K
What the payments were for
- Consulting fees$90013%
- Speaking & faculty fees$5,17575%
- Travel & lodging$5788%
- Food & beverage$2654%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BTG International Inc. | 5 | $5,991 |
| Bayer | 1 | $900 |
| Novocure Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,918 in reported general payments places this provider in the 65th percentile of 29 medical oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 154 | $18,384 |
| EliquisApixaban | 15 | $10,812 |
| Levetiracetam | 166 | $3,756 |
| Lamotrigine ErLamotrigine | 11 | $2,407 |
| Gabapentin | 91 | $1,623 |
| Dexamethasone | 74 | $1,523 |
| Pregabalin | 81 | $1,205 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 25 | $992 |
| Methylphenidate Hcl | 34 | $756 |
| Topiramate | 34 | $652 |
| Sertraline Hcl | 34 | $574 |
| Nortriptyline Hcl | 27 | $398 |
| Ondansetron Hcl | 33 | $307 |
| Mirtazapine | 17 | $257 |
| Oxcarbazepine | 21 | $205 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Charleston
- Albert LockhartCharleston$54K
- Gene SaylorsCharleston$26K
- Mariam AlexanderCharleston$23K
- Theodore GourdinCharleston$21K
- John KaczmarCharleston$20K
- Kevin BeckerCharleston$9K
- Carolyn BrittenCharleston$2K
- Rodney WilliamsCharleston$1K
- Oleksandra LupakCharleston$313
- Michael LillyCharleston$249
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.